Vicore Pharma Holding AB (STU:6Y4) Cash And Cash Equivalents : €29.65 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB Cash And Cash Equivalents?

Vicore Pharma Holding AB's quarterly cash and cash equivalents declined from Mar. 2024 (€38.10 Mil) to Jun. 2024 (€31.77 Mil) but then stayed the same from Jun. 2024 (€31.77 Mil) to Sep. 2024 (€29.65 Mil).

Vicore Pharma Holding AB's annual cash and cash equivalents declined from Dec. 2021 (€28.64 Mil) to Dec. 2022 (€23.36 Mil) but then increased from Dec. 2022 (€23.36 Mil) to Dec. 2023 (€29.83 Mil).

Vicore Pharma Holding AB Cash And Cash Equivalents Historical Data

The historical data trend for Vicore Pharma Holding AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Cash And Cash Equivalents Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

17.90

24.44

28.64

23.36

29.83

Vicore Pharma Holding AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash And Cash Equivalents	Get a 7-Day Free Trial															29.68	29.83	38.10	31.77	29.65

Vicore Pharma Holding AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Vicore Pharma Holding AB (STU:6Y4) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Vicore Pharma Holding AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

VICO:Sweden

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is as a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. The company also has an investigational medical device in clinical development namely, Almee which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines